Suppr超能文献

64例嗅神经母细胞瘤患者的长期生存结果及治疗经验

Long-Term Survival Outcomes and Treatment Experience of 64 Patients With Esthesioneuroblastoma.

作者信息

Zeng Qian, Tian Yifu, He Yihong, Xie Qiongxuan, Ou Ludi, Wang Min, Chen Wen, Wei Rui

机构信息

Department of Oncology, Xiangya Hospital, Central South University, Changsha, China.

National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.

出版信息

Front Oncol. 2021 Mar 4;11:624960. doi: 10.3389/fonc.2021.624960. eCollection 2021.

Abstract

Esthesioneuroblastoma (ENB) is a rare sinonasal malignancy, lacking a unified staging system and treatment. Management at a single center was retrospectively evaluated to inform future treatment options and prognostic factors. Clinical data of 64 consecutive ENB patients, including prognostic factors and treatment methods, were reviewed retrospectively. Data were collected to calculate overall survival (OS) and progression free survival (PFS). The majority of tumors 84.4% were within Kadish C stage, 79.7% were within T3 or T4, and 64.0% were within Hyams grade III or IV. A total of 50 (78.1%) patients received surgery and combined radiotherapy with or without chemotherapy, 10 (15.6%) received surgery with or without chemotherapy alone, and 4 (6.3%) received radiotherapy with or without chemotherapy alone. The majority of patients (79.7%) underwent endoscopic resection (endoscopic and endoscopically assisted). Surgery combined with radiotherapy with or without chemotherapy resulted in significantly better OS (84.4 vs. 50.6%, 84.4 vs. 37.5%) compared to surgery alone and radiotherapy alone ( = 0.0064). Endoscopic surgery group (endoscopic and endoscopically assisted) resulted in significantly better 5-year PFS (61.7 vs. 22.2%) compared to the open surgery group ( < 0.001). Although endoscopic surgery group was not a statistically significant predictor of 5-year OS ( = 0.54), the 5-year OS was 79.3% for the endoscopic surgery group and 76.2% for the open surgery group. A Cox regression analysis identified intracranial extension and surgery combined with radiotherapy as independent factors affecting 5-year OS while cervical lymph node metastasis and Hyams grade IV as independent factors affecting 5-year PFS. Our findings suggest that surgery combined with radiotherapy is the best treatment approach for ENB. For advanced tumors, endoscopic surgery is an effective treatment, and its survival rate is equal to or better than open surgery.

摘要

嗅神经母细胞瘤(ENB)是一种罕见的鼻窦恶性肿瘤,缺乏统一的分期系统和治疗方法。对单一中心的治疗情况进行回顾性评估,以指导未来的治疗选择和预后因素分析。回顾性分析了64例连续的ENB患者的临床数据,包括预后因素和治疗方法。收集数据以计算总生存期(OS)和无进展生存期(PFS)。大多数肿瘤(84.4%)处于卡迪什C期,79.7%处于T3或T4期,64.0%处于海姆斯III级或IV级。共有50例(78.1%)患者接受了手术联合放疗,可联合或不联合化疗,10例(15.6%)仅接受手术,可联合或不联合化疗,4例(6.3%)仅接受放疗,可联合或不联合化疗。大多数患者(79.7%)接受了内镜切除术(内镜及内镜辅助手术)。与单纯手术和单纯放疗相比,手术联合放疗,可联合或不联合化疗,其OS显著更好(84.4%对50.6%,84.4%对37.5%)(P = 0.0064)。与开放手术组相比,内镜手术组(内镜及内镜辅助手术)的5年PFS显著更好(61.7%对22.2%)(P < 0.001)。虽然内镜手术组并非5年OS的统计学显著预测因素(P = 0.54),但内镜手术组的5年OS为79.3%,开放手术组为76.2%。Cox回归分析确定颅内扩展和手术联合放疗是影响5年OS的独立因素,而颈部淋巴结转移和海姆斯IV级是影响5年PFS的独立因素。我们的研究结果表明,手术联合放疗是ENB的最佳治疗方法。对于晚期肿瘤,内镜手术是一种有效的治疗方法,其生存率等于或优于开放手术。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9360/7969639/3157b3f7be00/fonc-11-624960-g0001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验